Korea Research Institute of Bioscience and Biotechnology

Joo Heon Kim

Kyung Seop Ahn

Sei Ryang Oh

So Young Kim

Jae Wha Kim

Hyeong Kyu Lee

Doo Young Kim

Jung Hee Kim

Mi Jin Kim

Gyoon Hee Han

In-Sung Song

Ho Bum Kang

Joong Ku Lee

Ok Kyoung Kwon

Hyun Woo Oh

Jin-Man Kim

Gui Hua Quan

Bo Young Park

Sang Ku Lee

Jae Sung Song

Soon Ja Choi

Jeong-Min Kim

Byung Sun Min

Cheol-Hee Kim

Da Jung Ji

So-Young Jeong

Hyun-Taek Kim

Nam-Soon Kim

Hea Young Park

Gun Cheol Kim

Guang Hai Shen

Eun Ah Kim

Soo Young Jun

Ga Hee Ha

Jang Mi Sun

Jae Jong Go

Gui Hua Natural Medicines Research Center Quan

Gyoon Hee 209-1702 Sinyeongtong Hyundai Apt Han

San Ku Lee

The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis

The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.

Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer

The present invention relates to a composition comprising an extract of, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract ofand the tiarellic acid isolated therefrom shows the inhibitory effect on the LTCrelease in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

[object Object]

Growing community of inventors

Daejeon, South Korea

Joo Heon Kim